Related introduction of Inluriyo (Imlunestrant): What is it a medicine for?

Inluriyo (Imlunestrant) is a novel selective estrogen receptor antagonist designed for the treatment of patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), and ESR1-mutated advanced or metastatic breast cancer (MBC). These patients had disease progression despite receiving at least one endocrine therapy. Metastatic breast cancer is a type of cancer in which cancer cells have spread from the original tumor to other parts of the body. Some breast cancer patients will have ESR1 gene mutations, which lead to abnormally active estrogen receptors and further promote the growth of cancer.

Inluriyo has a unique mechanism of acting as a selective estrogen receptor degrader by binding to estrogen receptor alpha (the protein encoded by the ESR1 gene) to achieve receptor degradation and elimination. This process effectively inhibits estrogen-driven cancer growth, particularly in cancers where ESR1 mutations result in persistent receptor activity, demonstrating significant therapeutic efficacy.

The U.S. Food and Drug Administration (FDA) approved the use of Inluriyo based on data from the EMBER-3 trial. The trial results show that in patients with MBC with ESR1 mutations, Inluriyo monotherapy can reduce the risk of disease progression or death by 38% compared with traditional endocrine therapy. This achievement marks Inluriyo's important position in the field of breast cancer treatment.

Inluriyo is taken as a once-daily tablet on an empty stomach to ensure optimal absorption. Although its effect in treatment is significant, attention should also be paid to possible laboratory abnormalities, such as decreased hemoglobin, decreased calcium, neutropenia, increased liver enzymes (AST and ALT), increased triglycerides and cholesterol, and decreased platelets.

In short,Inluriyo provides a new treatment option for patients with estrogen receptor-positive, HER2-negative, and ESR1-mutated advanced or metastatic breast cancer, showing good clinical effects and safety, and bringing new hope for the treatment of such patients.

Reference materials:https://www.drugs.com/inluriyo.html